SOUTH SAN FRANCISCO, Calif., Dec. 10, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
"This expanded data set supports our belief in the potential of carfilzomib to treat late-stage patients with relapsed and refractory multiple myeloma," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals.
Abstract #1877: Multivariate Modeling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib
In an analysis of 430 patients from Phase 2 studies, a highly significant dose-response relationship for carfilzomib was observed across key efficacy endpoints including the primary endpoint of overall response rate (ORR), as well as duration of response (DOR), time to progression (TTP), progression-free survival (PFS) and overall survival (OS). These observations were confirmed and quantified using a statistically rigorous, multivariate analysis. The dose response relationship was also apparent in the magnitude of response (partial response or better) across study participants. While a corresponding dose-toxicity analysis is ongoing, carfilzomib has been shown to have a similar tolerability profile at 20mg/m(2) and 27mg/m(2) doses. These findings are being further assessed in clinical trials evaluating higher dosing regimens.
Abstract #1876: Integrated Safety Data from Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma: An Updated Analysis
In an analysis of 526 patients, the authors con
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved